Physician and CEO, Chicago Allergy Center, and board director at American Lung Association

 vaccination rates remain low even as the virus settles into a predictable twice-a-year pattern. In this 

 interview, allergist Juanita Mora, MD, unpacks the American Lung Association's COVID-19 prevention campaign, including who qualifies for a booster now, an underused antiviral prophylaxis option, and the specialist's role in closing persistent vaccination gaps.

ALA: Why COVID-19 Boosters Matter Now, With Juanita Mora, MD

COVID-19 antiviral use remains under 15%, and adult vaccination rates were only ~18% this past season

High-risk groups (age 65+, chronic lung/heart/kidney disease, diabetes, immunocompromised) should consider a summer booster, since antibody protection lasts about 6 months

Antiviral prophylactic treatment is available for high-risk adults and immunocompromised children 12 and older

Specialists can help close vaccination gaps by reviewing COVID-19, flu, and RSV status at every visit

Patients can check eligibility for the updated COVID-19 vaccine at lung.org

Our vaccination rates have been low throughout the country for COVID-19 vaccinations, and I think out of sight is out of mind for a lot of people. Many people [feel] we're done with the pandemic, so we don't have to worry about COVID 19 anymore. What I tell patients though is COVID 19 has become like the flu; it's coming back every season. It's here to stay.

COVID-19 vaccination rates among adults remain low even as the virus has settled into a predictable, twice-yearly seasonal pattern. According to CDC data cited in the American Lung Association's recently launched prevention campaign, only 18% of adults received a COVID-19 vaccine during the 2025–26 respiratory virus season — dropping to 31% among adults aged 65–74 and 37% among those 75 and older, the groups at highest risk for severe disease and hospitalization.1 Antiviral treatment is similarly underutilized: use remains below 15% among eligible patients, and only 16% receive treatment within the recommended 5-day window from symptom onset.1

Mora, of Chicago Allergy Center, and a medical expert spokesperson for the American Lung Association, spoke with 

 about the campaign and what specialist clinicians can do to close those gaps in their own practices.

COVID-19 has evolved from a pandemic threat into a predictable endemic respiratory virus — one that now circulates in 2 distinct seasonal waves per year, much like influenza and RSV. That shift has direct implications for how clinicians should counsel patients about booster timing. Vaccine-induced antibody protection against severe disease typically wanes over approximately 6 months, meaning the twice-yearly pattern of circulation aligns closely with the protection window from a single vaccine dose. For high-risk patients — those aged 65 and older, and those with chronic lung disease (including asthma, COPD, interstitial lung disease, cystic fibrosis, and pulmonary hypertension), heart disease, diabetes, chronic kidney disease, or immunocompromising conditions — a summer booster is a clinically reasonable consideration even if they received the fall/winter vaccine. Adults 65 and older are now formally recommended to receive 2 doses of the 2025–26 COVID-19 vaccine at least 6 months apart.1

Beyond vaccination, the ALA campaign highlights 2 prophylactic options that remain largely unknown to patients and underutilized even among clinicians. Ensitrelvir is an oral antiviral approved for post-exposure prophylaxis in individuals aged 12 and older who have had close contact with a COVID-19-positive person. It is taken over 5 days, with 3 tablets on day 1 and 1 tablet on days 2 through 5. Pemivibart is an intravenous monoclonal antibody approved for pre-exposure prophylaxis in moderately or severely immunocompromised patients for whom vaccination is likely to be insufficient. Both options represent an underappreciated layer of protection for high-risk populations who may not mount adequate vaccine responses or who face particularly high consequences from breakthrough infection.1

For specialists — pulmonologists, allergists, rheumatologists, cardiologists, and others managing patients with the chronic conditions that confer high COVID-19 risk — Mora emphasized that every clinical encounter represents an opportunity to address vaccination status comprehensively. Reviewing COVID-19, flu, and RSV vaccination status at each visit, correcting misconceptions about whether COVID-19 vaccines are still needed, and directing patients to the ALA's eligibility checker at lung.org are all actionable steps that do not require adding time to an already compressed appointment.

Editor’s note: Mora has no relevant disclosures to report.

American Lung Association. American Lung Association highlights therapeutic options available to prevent and treat COVID-19 [press release]. July 30, 2026. 

https://www.prnewswire.com/news-releases/american-lung-association-highlights-therapeutic-options-available-to-prevent-and-treat-covid-19-302835975.html

American Lung Association. Prevent COVID-19. 

https://www.lung.org/lung-health-diseases/lung-disease-lookup/covid-19/prevention

Articles

COVID-19 vaccine uptake remains poor despite a now-endemic, twice-yearly circulation pattern resembling influenza/RSV. Only 18% of adults received a 2025–26 season dose, with modestly higher coverage in older high-risk groups; antiviral treatment is also underused and often delayed beyond five days. Antibody-mediated protection wanes around six months, supporting consideration of a summer booster for high-risk patients; adults ≥65 are recommended two 2025–26 doses six months apart. Additional prophylaxis includes ensitrelvir post-exposure and pemivibart pre-exposure for select immunocompromised patients.

Allergist Juanita Mora, MD, breaks down the ALA's COVID-19 prevention campaign — who needs a booster now, and how specialists can close the gap.

COVID-19

COVID-19 page, resources on the topics of medical news and expert insight into coronavirus can be found. Content includes articles, interviews, videos, podcasts, and breaking news on COVID-19 research, treatment, and drug development.

Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Strategic Alliance Partnership

Merve Karaca Şahin, from University of Health Sciences, Prof. Dr. Cemil Tascioglu City Hospital in Istanbul, Turkey.

avoidant/restrictive food intake disorder (ARFID)

-related eating behaviors than healthy peers, driven primarily by picky eating and fear-based avoidance rather than appetite loss, according to a recent study.

 Food Allergy Linked to ARFID-Related Eating Behaviors in Children

Feeding difficulties in pediatric food allergy have been reported across a wide range, from 13.6% to 40%, but prior studies relied on heterogeneous terminology and diagnostic instruments and skewed toward non-IgE-mediated phenotypes.

No prior study had applied the Nine Item Avoidant/Restrictive Food Intake Disorder Screen–Parent Report (NIAS-PR) to an IgE-mediated food allergy population, leaving a gap in standardized data for allergists managing selective or avoidant eaters.¹

“Importantly, their appetite scores were similar to those of healthy children, so the main issue may not be low appetite,” Merve Karaca Şahin, from Prof. Dr. Cemil Tascioglu City Hospital in Istanbul, Turkey, told 

 “Instead, fear and picky eating may limit the foods children feel safe eating.”

NIAS-PR Scores and Eating Behavior Domains in Food Allergy

The single-center, prospective, controlled study enrolled 234 children aged 2 to 9 years, including 117 with physician-diagnosed food allergy and 117 age- and sex-matched healthy controls, evaluated at the Pediatric Immunology and Allergy Outpatient Clinic of University of Health Sciences, Prof. Dr. Cemil Tascioglu City Hospital between September 2025 and February 2026.¹ Parents completed the NIAS-PR, a validated tool assessing 3 domains: picky eating, appetite, and fear of aversive consequences from eating.¹

Median total NIAS-PR scores were significantly greater in the food allergy group than in controls (17 [IQR, 11-24] vs 12 [IQR, 7-18]; 

 <.001).¹ The difference was driven by picky eating and fear subscale scores (both 

 <.001), whereas appetite subscale scores did not differ significantly between groups (

 =.311).¹ Karaca Şahin said this pattern challenges assumptions that food allergy uniformly suppresses interest in eating, noting a child may enjoy eating yet restrict intake to a narrow list of foods perceived as safe.

Growth, Asthma, and Reaction Severity Tied to ARFID Risk

What did the NIAS-PR study find in children with food allergy?

Children with food allergy had significantly higher NIAS-PR total, picky eating, and fear subscale scores than healthy controls, while appetite scores did not differ.

Does food allergy suppress appetite in children?

Not according to this study; appetite-related items were similar between children with food allergy and controls, suggesting fear and picky eating, not appetite loss, drive ARFID-related behavior.

When should a positive ARFID screen prompt referral in children with food allergy?


Karaca Şahin recommends referral when restriction is accompanied by faltering growth, weight loss, a narrow food list, persistent fear, or difficulty reintroducing tolerated foods, rather than from the score alone.

Children with food allergy also demonstrated significantly lower weight-for-age (−0.20 ± 1.10 vs 0.26 ± 1.05; 

 =.001) and height-for-age z-scores (−0.40 ± 1.18 vs 0.15 ± 1.18; 

 <.001) compared with controls. BMI z-scores did not differ significantly between groups (

 =.117).¹ Karaca Şahin said the study could not separate how much of this growth difference stemmed from ARFID-related behaviors versus the elimination diet itself, calling the effect likely multifactorial given the absence of detailed dietary intake data.

Within the food allergy group, children with comorbid asthma (n = 34) had greater total NIAS-PR scores than those without asthma (19 [IQR, 14-39] vs 16 [IQR, 10-22]; 

 =.043).1 Karaca Şahin cautioned against overinterpreting the modest link, noting that the study was not designed to explain the association and that, for now, it should be viewed as an intriguing lead for future research. Children with a history of urticaria (

 =.014) also scored significantly greater on the fear subscale.

“This makes sense clinically because anaphylaxis can be life-threatening and very frightening, while urticaria is often sudden, visible, and memorable,” Karaca Şahin said. “These reactions make children and their families feel that eating is unsafe. Over time, this may lead to more food avoidance.”

Because no validated NIAS-PR cutoff exists for diagnosing ARFID in this population, Karaca Şahin said a positive screen alone should not trigger referral; instead, she flags faltering growth, weight loss, a very narrow food list, persistent fear, or difficulty reintroducing a food after a negative oral food challenge as signals warranting evaluation by feeding and mental health specialists.

Related Research on ARFID Risk in Pediatric Food Allergy

separate research showing children with and without food allergy screened positive for possible ARFID at similar rates

 (23% vs 21%) underscoring ongoing uncertainty about how allergy-specific this risk truly is.

 In a population-based Australian birth cohort study, possible ARFID among children with food allergy was more common in those with anaphylaxis or an epinephrine autoinjector prescription, and current hay fever was linked to greater rates of both possible ARFID and possible ARFID inclusive of food allergy anxiety.

Karaca Şahin M, Çalışkan N, Şarman HT, et al. Fear and picky eating-related ARFID behaviors in children with food allergy. 

Hill SA, Nurmatov U, DunnGalvin A, et al. Feeding difficulties in children with food allergies: An EAACI Task Force Report. 

Ciciulla D. Q&A: 1 in 5 children with food allergy screen positive for possible ARFID. HCPLive. Published August 6, 2026. Accessed August 6, 2026. 

https://www.hcplive.com/view/1-in-5-children-food-allergy-screen-positive-possible-arfid

Videos

A prospective controlled study of 234 children finds food allergy raises ARFID-related picky eating and fear scores, but not appetite loss.

Allergy

Allergy condition center page is a comprehensive resource for clinical news and insights on allergic and inflammatory diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for food and seasonal allergies, as well as allergic asthma and related conditions.

Food Allergy

Psychiatry

Psychiatry condition center page is a comprehensive resource for clinical news and insights on mental illnesses. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for depression, schizophrenia, bipolar disorder, anxiety, and more.

Food Allergy Linked to ARFID-Related Eating Behaviors in Children

Alex Hillenbrand is an assistant editor for 

. She earned her BA in English from Lafayette College in 2023 and went on to write for pop culture, entertainment, and sports media outlets before joining MJH Life Sciences in 2025. In her free time, Alex enjoys cooking, going on walks, and meeting new people. Contact her at mjhlifesciences.com.

and a discontinued development program in the same condition.

 granted priority review to Agios' mitapivat sNDA for 

, with a PDUFA date of November 1, 2026, which, if approved, would become the first oral pyruvate kinase activator for the condition. About 2 weeks later, Agios discontinued development of tebapivat, a separate pyruvate kinase activator, in sickle cell disease after phase 2 results did not show sufficient differentiation from placebo. HCPLive also spoke with Wendy Stock, MD, about the FDA's approval of Orca-T (Tregzi), a precision-engineered cell therapy for allogeneic transplant in adults with hematological malignancies.

Below is a summary of the July 2026 stories in hematology, covering regulatory decisions and trial data in sickle cell disease and cell therapy for transplant-related graft-versus-host disease.

FDA Grants Priority Review to Agios' Mitapivat sNDA for Sickle Cell Disease

On July 7, 2026, the FDA granted priority review to Agios' supplemental NDA for mitapivat, an oral pyruvate kinase activator, in sickle cell disease, with a PDUFA date set for November 1, 2026. Mitapivat is already approved in the US for two other hemolytic anemias, pyruvate kinase deficiency and thalassemia.

Agios Ends Tebapivat Development in Sickle Cell Disease After Phase 2

On July 21, 2026, Agios discontinued development of tebapivat in sickle cell disease after phase 2 results showed hemoglobin responses across active doses that were not sufficiently differentiated from placebo. The company said the decision was based on lack of differentiation rather than safety or tolerability concerns, and that it will continue to focus its sickle cell disease efforts on mitapivat.

FDA Approves Orca-T After Phase 3 Trial Improves Chronic GVHD-Free Survival

In this interview, Wendy Stock, MD, discusses the FDA approval of Orca-T (Tregzi), a precision-engineered allogeneic regulatory T-cell therapy for adults with hematological malignancies undergoing matched-donor transplant. The conversation covers phase 3 data showing improved chronic graft-versus-host disease-free survival compared with conventional allogeneic transplant, along with open questions on cost, longer-term relapse control, and how the therapy compares with existing GVHD prevention approaches

July brought divergent pyruvate kinase activator updates in sickle cell disease, with mitapivat advancing under FDA priority review and a November 1, 2026 PDUFA date, while tebapivat was discontinued after phase 2 efficacy failed to separate meaningfully from placebo. In transplant, FDA approval of Orca-T (Tregzi) for adults with hematologic malignancies undergoing matched-donor allogeneic transplant highlighted phase 3 evidence of improved chronic GVHD–free survival versus conventional approaches, alongside practical uncertainties around cost, durability, relapse risk, and positioning versus established GVHD prophylaxis.

Hematology in July 2026: FDA priority review for Agios' mitapivat in sickle cell disease, plus Orca-T's approval for GVHD-free survival.

Hematology

FDA News

Sickle Cell

Sickle Cell condition center page, resources on the topics of medical news and expert insight into sickle cell disease can be found. Content includes articles, interviews, videos, podcasts, and breaking news on sickle cell research, treatment, and drug development.

3 Hematology Headlines You Missed in July 2026

Diana Isaacs, PharmD, is an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and codirector of Endocrine Disorders in Pregnancy at the Cleveland Clinic.

Retatrutide Cuts Weight, Cardiovascular Disease Risk in TRIUMPH-3

Triple hormone receptor agonism continues to show cardiometabolic promise in 

 treatment, with new phase 3 data indicating retatrutide can pair substantial weight loss with meaningful reductions in cardiovascular risk factors among patients with established 

On a recent episode of Diabetes Dialogue, cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, reviewed topline results from the phase 3 TRIUMPH-3 trial evaluating retatrutide, a glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptor triple agonist, in adults with obesity and cardiovascular disease.

Watch the full episode on the TRIUMPH-2 and TRIUMPH-3 data

TRIUMPH-3 enrolled >1900 participants with class II or III obesity (body mass index of 35 or higher) and established cardiovascular disease, randomizing them across global sites to 9 mg, 12 mg, or placebo over 80 weeks. The 9 mg dose produced average weight loss of 22%, or 53 pounds, and the 12 mg dose produced 23%, or 56 pounds, compared with 3% among patients receiving placebo. Weight loss was somewhat less pronounced than in TRIUMPH-1, where the highest dose reached 28.3%, a difference investigators partly attributed to inclusion of some participants with 

The 12 mg dose was also associated with a 37% reduction in triglycerides, a 17% reduction in non-high-density lipoprotein cholesterol, a 9.3 mmHg reduction in systolic blood pressure, a 19 cm reduction in waist circumference, and a 51% reduction in high-sensitivity C-reactive protein. 3-point and 5-point major adverse cardiovascular event outcomes trended favorably but did not reach statistical significance, a limitation the hosts attributed to the trial's relatively short 80-week duration compared with dedicated cardiovascular outcomes trials such as the 5-year REWIND study of dulaglutide. A properly designed cardiovascular outcomes trial will be needed to confirm whether the risk-factor improvements translate into fewer events.

Gastrointestinal effects were common, with diarrhea reported in up to 34% of participants, nausea in up to 28%, constipation in 17%, decreased appetite in 17%, and vomiting in up to 16%, a profile consistent with other incretin-based therapies. Discontinuation rates were 3.8% with the 4 mg dose, 11% with 9 mg, and 7.7% with 12 mg, compared with nearly 5% among patients receiving placebo. The hosts noted patients who discontinue 1 incretin agent because of side effects may tolerate a different 1, underscoring the value of having multiple agents available in practice.

The findings add to a growing body of evidence supporting triple agonist therapy as a tool for addressing weight and cardiometabolic risk together in patients with established cardiovascular disease, even as the topline data lacked continuous glucose monitoring metrics investigators hope will appear in the trial's full readout. As increasingly potent incretin-based agents advance through a crowded pipeline, the field is beginning to weigh whether older, less potent molecules will retain a lasting clinical role.

Editors’ Note: Isaacs reports disclosures with Dexcom, Abbott, Lilly, Novo Nordisk, Medtronic, Insulet, and others. Bellini reports disclosures with Abbott Diabetes Care, MannKind, Povention Bio, and others.

Eli Lilly. Lilly’s triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C. July 23, 2026. Accessed August 4, 2026. 

https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-successful-two-additional

In this segment from the latest episode of Diabetes Dialogue, Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss topline data from the TRIUMPH-3 trial of retatrutide.

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

This page also hosts content previously published by EndocrinologyNetwork. 


Type 2 Diabetes

Obesity Management

Obesity Management condition center page, resources on the topics of medical news and expert insight into clinical weight management can be found. Content includes articles, interviews, videos, podcasts, and breaking news on obesity research, treatment, and drug development.

Victoria Johnson joined MJH Life Sciences in 2020 and has written for NeurologyLive, CGTLive, and is now an assistant managing editor for HCPLive and RheumatologyLive. She doesn’t have enough time for her numerous hobbies. You can reach her at vjohnson@mjhlifesciences.com.

The US Food and Drug Administration (FDA) has accepted a supplemental Biologics License Application (sBLA) for 

 (Enflonsia), Merck's extended half-life monoclonal antibody, to expand its indication to include prevention of respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD) in children under 2 years of age at increased risk for severe RSV through their second RSV season, according to the company.

The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of March 22, 2027, for the expanded indication.

 Clesrovimab-cfor is currently approved only for infants born during or entering their first RSV season, delivered as a single, non-weight-based 105 mg dose.

 The European Medicines Agency (EMA) accepted a parallel application for the same expanded population in July 2026.

“For some children, the potentially serious impact of RSV does not stop after their first RSV season,” said Macaya Douoguih, MD, MPH, vice president and therapeutic area head of global clinical development at Merck Research Laboratories.

 “The recent FDA and EMA regulatory filings represent important opportunities to help expand protection with ENFLONSIA for vulnerable children under 2 years of age during their second RSV season, potentially further reducing the significant burden of RSV on families and health care systems.”

How Was Clesrovimab-cfor Studied For Second-Season Dosing?

Both applications draw on the phase 3 SMART trial (MK-1654-007; NCT04938830), a randomized, partially-blind, palivizumab-controlled study evaluating the safety, efficacy, and pharmacokinetics of clesrovimab-cfor in infants and children at increased risk for severe RSV disease across 2 RSV seasons.

 The trial enrolled early preterm infants (younger than 29 weeks gestational age), moderate preterm infants (29 to 35 weeks gestational age), and infants with chronic lung disease (CLD) of prematurity or congenital heart disease (CHD) of any gestational age.

In season 1, participants were randomized 1:1 to a single 105 mg intramuscular dose of clesrovimab-cfor (n = 502) or monthly intramuscular palivizumab (n = 501).

 Eligible participants, defined as children under 2 years of age with CLD, CHD, or early or moderate preterm birth with certain risk conditions, received an additional open-label 210 mg dose of clesrovimab-cfor in season 2 (n = 276), including 138 who received clesrovimab-cfor and 138 who received palivizumab in season 1.

 Nearly all season 2 recipients, 99%, had CLD (n = 229) or CHD (n = 43).

What indication expansion is Merck seeking for clesrovimab-cfor?

Merck is seeking to expand the clesrovimab-cfor (Enflonsia) label to include prevention of RSV lower respiratory tract disease in children under 2 years of age at increased risk for severe RSV through their second RSV season, beyond its current first-season indication.

What is the PDUFA date for the clesrovimab-cfor sBLA?

The FDA has set a target action date of March 22, 2027.

What dose is used for a second RSV season?

In the SMART trial, eligible children received an additional open-label 210 mg dose of clesrovimab-cfor for their second RSV season, compared with the 105 mg dose used in season 1.

What is Safety Profile of Clesrovimab-cfor?

In the published SMART trial results, RSV-associated medically attended lower respiratory infection through day 180 after the season 2 dose occurred in 7.3% of recipients (95% CI, 4.4%-11.4%), compared with a season 1 incidence of 3.2% (95% CI, 1.8%-5.2%) for clesrovimab-cfor and 3.4% (95% CI, 2.0%-5.6%) for palivizumab through day 150.

 The study authors concluded clesrovimab-cfor was well tolerated across both seasons, supporting its use in children who remain at risk for severe RSV disease into a second season.

Per its current US label, the most common adverse reactions associated with clesrovimab-cfor are injection-site erythema (3.8%), injection-site swelling (2.7%), and rash (2.3%).

 Serious hypersensitivity reactions, including anaphylaxis, have been observed with other human IgG1 monoclonal antibodies, and clesrovimab-cfor is contraindicated in infants with a history of serious hypersensitivity to any component of the product.

 The FDA originally approved clesrovimab-cfor in June 2025, followed by European Commission approval in April 2026, and the agent is now approved in more than 40 countries for use in infants during their first RSV season.

Clesrovimab-cfor is Merck's only RSV preventive option administered at a fixed dose regardless of weight, designed to provide direct, rapid, and durable protection through 5 months.

 Regulatory filings for the expanded second-season indication are underway in additional countries beyond the US and EU, alongside continued filings for first-season approval where the agent is not yet authorized.

Merck. U.S. FDA Accepts sBLA for ENFLONSIA™ (clesrovimab-cfor) to Update its Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease Indication to Include Children Under Two Years at Increased Risk for Severe RSV for Their Second Season. Published August 6, 2026. Accessed August 6, 2026. https://www.merck.com/news/u-s-fda-accepts-sbla-for-enflonsia-clesrovimab-cfor-to-update-its-respiratory-syncytial-virus-rsv-lower-respiratory-tract-disease-indication-to-include-children-under-two-years-at-increa/

Zar HJ, et al. Clesrovimab in Infants at Increased Risk for Severe Disease During 2 RSV Seasons: A Randomized Clinical Trial. JAMA Pediatr. Published online July 20, 2026. doi:10.1001/jamapediatrics.2026.2760

The FDA accepted an sBLA for clesrovimab-cfor (Enflonsia) to extend RSV LRTD prevention to children <2 years at elevated risk for severe RSV through a second season, with a PDUFA date of March 22, 2027; the EMA accepted a parallel filing in July 2026. Evidence derives from the phase 3 SMART trial comparing single-dose clesrovimab vs monthly palivizumab in season 1, followed by an open-label 210 mg season-2 dose in eligible participants, predominantly CLD/CHD, with tolerability maintained across seasons.

Merck's sBLA seeks to extend clesrovimab-cfor (Enflonsia) coverage to children under 2 years at increased risk for severe RSV during their second season.

Infectious Disease

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on viruses, infections, and bacteria. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for COVID-19, influenza, vaccine-preventable diseases, and more.

Pediatrics

Pediatrics page, resources on the topics of medical news and expert insight into childhood health care can be found. Content includes articles, interviews, videos, podcasts, and breaking news on pediatric disease research, treatment, and drug development.

FDA Accepts sBLA for Clesrovimab-cfor in Second RSV Season

Stacey Rifkin-Zenenberg, DO, is a Pediatric Hematologist Oncologist in Hackensack, NJ. She has 30 years of experience and is board certified in Hospice Care and Palliative Medicine.

Stacey Rifkin-Zenenberg, DO, on gene therapy vs stem cell transplant and when to refer for sickle cell disease. 

With 2 Curative Pathways, Sickle Cell Intervention Can Start in Infancy

Linda Stein Gold, MD, is a dermatologist at Henry Ford Health. 

Linda Stein Gold, MD, discusses age-stratified ADORING data on tapinarof cream for atopic dermatitis, presented at the 2026 SPD Annual Meeting.

Atopic Dermatitis

Atopic Dermatitis condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatitis research, treatment, and drug development.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Age-Stratified ADORING Data Show Consistent Tapinarof Efficacy in Eczema

Chelsie Derman is an associate editor for 

who covers allergy and  psychiatry. She joined MJH Life Sciences in September 2023 after graduating from The College of New Jersey with a bachelor’s degree in journalism and professional writing. In her free time, she enjoys creative writing and reading.

The mRNA-based vaccine wins full approval for adults aged 50 to 64 years and accelerated approval for adults aged ≥ 65 years following unanimous VRBPAC backing.

mFLUSIVA Receives FDA Approval for Influenza in Adults 50 and Older

Ryan Livingston joined the MJH Life Sciences team in March of 2025, shortly after graduating from TCNJ with a bachelor’s degree in English. He enjoys creative writing, reading, and scuba diving. He can be reached at rlivingston@mjhlifesciences.com.

Combination therapy with navepegritide and lonapegsomatropin has demonstrated its efficacy in improving mean annualized growth velocity in pediatric patients.

Hormonal Disorders

Ascendis Reports 78-Week Data From COACH Trial for Achondroplasia

Saakshi Khattri, MD, is a board certified Dermatologist, Rheumatologist and Internist and one of only a handful of triple board-certified physicians across the US.

Saakshi Khattri, MD, discusses the comparable safety profile of risankizumab in psoriasis and psoriatic arthritis and the minimal need for routine laboratory monitoring.

Video Series

Consistent Safety Profile of Risankizumab Across Psoriasis and Psoriatic Arthritis

Mandana Khalili, MD, is Chief of Clinical Hepatology and Director of Clinical and Translational Research in Hepatology at San Francisco General Hospital, and directs the UCSF T32 Hepatology Training Program.

Mandana Khalili, MD, discusses how baseline motivation predicted alcohol reduction in a stepped treatment trial for liver disease patients.

Hepatology

Baseline Motivation Predicts Alcohol Reduction in Chronic Liver Disease

Linda Stein Gold, MD, discusses ADORING trial endpoints and remaining treatment gaps in the youngest patients with atopic dermatitis.

Q&A: Tapinarof Data Highlight Unmet Pediatric Needs in Atopic Dermatitis

Friedman breaks down the updated CSU guidelines and where omalizumab, dupilumab, and remibrutinib fit.

Urticaria

The HCPLive urticaria page is a comprehensive resource for clinical news and insights on chronic idiopathic urticaria and chronic spontaneous urticaria. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for urticaria, and more.

Navigating Second-Line Treatments in 2026 CSU Guidelines, With Adam Friedman, MD

FDA approval is based on phase 3 FirstLight and RadiantLight trials, the first therapy to directly restore orexin signaling in adults with NT1.

Sleep

On the HCPLive sleep page, resources on the topics of medical news and expert insight into sleep medicine can be found. Content includes articles, interviews, videos, podcasts, and breaking news on sleep apnea, insomnia, narcolepsy, and more.

FDA Approves Oveporexton (Orzeyful) for Narcolepsy Type 1

Oral encapsulated FMT increased peanut reactivity thresholds in 6 of 15 adults, tied to RORγt+ Treg cell expansion.

Latest News

ALA: Why COVID-19 Boosters Matter Now, With Juanita Mora, MD

Food Allergy Linked to ARFID-Related Eating Behaviors in Children

3 Hematology Headlines You Missed in July 2026

Retatrutide Cuts Weight, Cardiovascular Disease Risk in TRIUMPH-3

FDA Accepts sBLA for Clesrovimab-cfor in Second RSV Season